Recent clinical trials have reported that Sig-1R agonist Pridopidine has neuroprotective efficacy in treating motor deficits of HD patients (Lundin et al., 2010; Huntington Study Group, 2013; Reilmann et al., 2019). This evidence concerns the gene SIGMAR1 and Huntington disease.